← Press release
MAGNAPHARM AND ABBVIE ENTER INTO PARTNERSHIP FOR OPHTALMOLOGY AND EYE CARE PORTFOLIO IN TERRITORY OF CENTRAL AND EASTERN EUROPE
October 31st, 2022
MagnaPharm announces today the signature of a Distribution and Supply Agreement with AbbVie. Under the Agreement AbbVie has appointed MagnaPharm to market, promote and distribute AbbVie ophthalmology portfolio in 9 countries of Central and Eastern Europe.
The AbbVie ophtalmology portfolio includes prescription brands LUMIGAN, GANFORT, ALPHAGAN and COMBIGAN used in treatment of glaucoma and over-the-counter eye care brands REFRESH and OPTIVE.
“We, at MagnaPharm, are honored and excited to partner with AbbVie commercializing the ophthalmology portfolio in the countries of Central and Eastern Europe. Ophthalmology is one of our key specialties to be developed within upcoming years at regional level and AbbVie ophthalmology portfolio creates a strong backbone of our pipeline in this therapeutical field. The regional transaction signed between MagnaPharm and AbbVie will help us to accelerate the growth across the CEE region. We are sure that our local expertise will support the leading presence of AbbVie ophthalmology brands in geography of Central and Eastern Europe,” commented MagnaPharm’s CEO, Karol Michalak, PharmD.
About MagnaPharm: MagnaPharm is a pharmaceutical outsourcing group offering import, distribution, market access, marketing and medical promotion, regulatory services. MagnaPharm operates its own subsidiaries across Central and Eastern Europe and Balkans, covering 17 countries with its direct presence. With 570 employees and 2022 annual sales at175M Euro, MagnaPharm is one of the leading regional pharmaceutical out-sourcing companies representing global, international and specialty pharma companies in CEE and Balkans. MagnaPharm is managing and representing long list of global Rx and OTC brands invarious therapeutical areas such as dermatology, respiratory, gynaecology, neurology, haematology/oncology, diagnostics and self-medications.
For more information about MagnaPharm, please, visit: www.magnapharm.eu